Type of information | Equipment | Field procedures | Participant type | Definition of variable | Site participation | ||
---|---|---|---|---|---|---|---|
Malawi | S. Africa | Uganda | |||||
Demographics | Questionnaire | Face-to-face interview | all | Sex, age, education status, marital status | x | x | x |
Chronic disease history and family history | Questionnaire /medical records | Face-to-face interview | all | HTN, DM, CKD, Stroke, heart disease | x | x | x |
Treatment history | Patient report/records | Face-to-face interview | all | HTN, DM, CKD, Stroke, HIV,TB, Heart disease, Cancer, Backache | x | x | x |
Health behaviours | Patient report | Face-to-face interview | all | Tobacco use, alcohol consumption, Physical activity, vegetable, fruits, salt and water intake | x | Â | x |
Traditional medicine use | Questionnaire | Face-to-face interview | all | Use of herbs and traditional medicines | x | x | x |
Physical examination | Omron® SECA® Flexible tape SECA© scales | Clinical Examination in the field, machines calibrated weekly | all | BP (mmHg), waist and hip circumferences (cms), height (m), weight (Kgs) | x | x | x |
ABPM | ABPM spacelabs® | 24 h BP, 30 min interval day, 1 h interval night | Sample per eGFR quarter | BP wake periods and sleep periods | x |  | x |
BIA | Bodystat® | Tested in the field or clinic with participant, calibration weekly | all | Fat mass (kg), Lean mass (kg), Dry lean mass(kg), Total body water (L), Impedance at 50 KHZ (Ω) | x | x | x |
DXA SCAN | Hologic Discovery A. QDR 4500 Series | Whole body scan performed in clinical research clinic during iohexol testing | all | Lean Mass (g), Fat mass (g) Fat % and BMI | Â | x | Â |
Ultra sound scan | Logiq e | Performed at clinic | all | Probe 4c for kidneys and bladder and probe12L CIMT probe | Â | x | Â |
ECG | ECG 300A®/ MAC600® | ECG protocol followed | all | LVH using the Sokolow-Lyon criteria | x | x | x |
CBC | BC® | Venous blood draw | all | Total cell count, HB, MCV | x |  | x |
24 HR URINE | Cobas Roche® | urine using small bucket. | Select patients for 24 h proteinuria, salt and feasibility. | Volume (mls) Protein (mg) Creatinine (mmol/L) Na+ mmol/L |  |  | x |
Malaria screen | Malaria RDT® | Done in the community | all | Malaria infection | x |  | x |
CRP | Cobas® & BC® | Blood draw | all | CRP | x |  | x |
Hepatitis B | Cobas® ABBOTT (i1000SR) | Blood draw | all | HepB SAg | x | x | x |
Hepatitis C | Cobas® (Uganda), HCV antibody rapid test (Malawi) | Blood draw | all | HepC Ab | x |  | x |
ASOT | Cobas® & BC® | Blood draw | All | > 300 |  |  | x |
HIV screen | Alere Dertemine-Stat-pak-Bio line & Abbott Determine | MOH serial testing algorithm | all | HIV status | x | x | x |
Schistosomiasis | Microscopy | Examination of centrifuged urine | all | Schistosoma hematobium | x | x | x |
Microalbuminuria | CLINITEK® + analyser & Cobas® & BC® | ACR | all | Urine ACR | x | x | x |
Urine analysis | Clinitek® & UroColor | Early morning urine | all | Protein, blood, glucose, WBCs, QuickVue Hcg Urine for pregnancy | x | x | x |
Lipid profile | Cobas® & BC® | Blood draw | all | Cholesterol, LDL, HDL, TGs | x |  | x |
RBS | BC® | Point of care testing (Uganda $ SA) | all | Diabetes > 11.1 or on medical treatment | x | x | x |
HBA1C | Cobas® & BC® | Blood draw | All | 6.5% or on treatment | x |  | x |
Creatinine | Cobas® & BC® | Jaffe and IDMS | all | For eGFR estimation | x | x | x |
Cystatin-C | Cobas® |  | all | For eGFR estimation | x | x | x |
Iohexol | Omnipaque 300 mg I/ml Healthcare® HPLC® | Clinic based blood draws at 5, 120, 180 and 240 min after administration | all | Measured GFR | x | x | x |
Iohexol, DBS | DBS® | DBS by finger prick at 120 and 240 min | 300 selected by eGFR | Validation of measured GFR technique |  |  | x |
Aldosterone/Renin | Cobas Roche® |  | Selected population |  | x |  | x |